Executive interview – InMed Pharmaceuticals

Published on 26 June 2019

In this interview, Eric Adams, chief executive officer of InMed Pharmaceuticals, provides an overview of InMed’s differentiated biosynthesis platform and its therapeutic pipeline of cannabinoids.

InMed Pharmaceuticals (TSX: IN) is a Canada-based biopharmaceutical company focused on manufacturing and developing cannabinoids. Its biosynthesis platform has the potential to produce cannabinoids at a lower cost and with improved purity compared to currently used methods. The company is also developing a proprietary pipeline, including INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.

Share this with friends and colleagues